XTX Topco Ltd Buys New Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

XTX Topco Ltd bought a new position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) in the second quarter, HoldingsChannel.com reports. The institutional investor bought 13,278 shares of the biopharmaceutical company’s stock, valued at approximately $75,000.

Several other institutional investors have also recently added to or reduced their stakes in VNDA. SageView Advisory Group LLC bought a new stake in shares of Vanda Pharmaceuticals in the 1st quarter valued at $34,000. Meeder Asset Management Inc. bought a new stake in Vanda Pharmaceuticals in the second quarter valued at $39,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Vanda Pharmaceuticals by 65.9% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,045 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 4,387 shares during the period. SG Americas Securities LLC bought a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth about $61,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Vanda Pharmaceuticals by 18.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 2,425 shares during the period. 88.14% of the stock is owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Price Performance

NASDAQ:VNDA opened at $4.54 on Wednesday. Vanda Pharmaceuticals Inc. has a one year low of $3.30 and a one year high of $6.75. The company has a market cap of $264.64 million, a PE ratio of -56.75 and a beta of 0.77. The firm has a 50-day moving average of $5.25 and a 200-day moving average of $5.17.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. The company had revenue of $50.47 million for the quarter. On average, equities research analysts expect that Vanda Pharmaceuticals Inc. will post -0.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Cantor Fitzgerald upped their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, August 1st. StockNews.com initiated coverage on Vanda Pharmaceuticals in a report on Monday. They issued a “hold” rating on the stock.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.